Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2024-12-14 M&A Activity
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
News release - English.pdf
M&A Activity Classification · 85% confidence The document is a press release announcing the final court order and expected closing of a corporate plan of arrangement (spin-out) of subsidiaries, which is a form of merger/acquisition or corporate restructuring transaction. It is not a routine financing update or mere publication notice, but an M&A-type transaction announcement.
2024-12-14 English
Material change report - English.pdf
Capital/Financing Update Classification · 87% confidence The document is a Material Change Report (Form 51-102F3) detailing updates to a non-brokered private placement offering (reduced price per unit, increased units, warrant terms), which is a financing/capital activity. This fits the Capital/Financing Update category (CAP).
2024-12-11 English
News release - English.pdf
Capital/Financing Update Classification · 90% confidence The document is a press release by BioVaxys announcing adjustments to a non-brokered private placement offering (repricing of units, increase in shares and warrants, use of proceeds), which constitutes a financing update covering fundraising and capital structure changes. This aligns with the definition of Capital/Financing Update (CAP).
2024-12-11 English
News release - English.pdf
Regulatory Filings
2024-12-05 English
Report of exempt distribution (45-106F1).pdf
Regulatory Filings
2024-11-25 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing that SpayVac for Wildlife, Inc. has scaled up its vaccine production capacity. It includes details about the production facility, recent shipments, and future plans. There are no financial statements, regulatory filings, or detailed financial data. The document is a corporate announcement about operational progress and partnership activities, not a financial report, regulatory filing, or management report. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is a general corporate news announcement about business development and capacity expansion. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2024-11-20 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.